Inhaled Insulin for Kids: Inside the INHALE-1 Trial
About this episode
The episode discusses the recent approval of inhaled insulin for children and the findings from the INHALE-1 trial.
In this episode of the TCOYD Podcast, Drs. Edelman and Pettus are joined by pediatric endocrinologist Dr. Jamie Wood, medical director of pediatric diabetes at Rainbow Babies & Children's Hospital and an investigator on the INHALE-1 trial, to discuss inhaled insulin in children and its place in pediatric practice. The conversation centers on the recent approval of Afrezza down to age six and what INHALE-1 actually demonstrated. Dr. Wood walks through the trial design, the A1C analysis, the FEV1 and pulmonary safety data, the weight and BMI findings, and the practical mechanics of dosing in a pediatric population. Rather than framing it as a replacement for injections or automated insulin delivery (AID), the discussion focuses on where this option fits, from the needle-averse newly diagnosed patient, to the teen trying to bolus discreetly during a 20-minute lunch period. Drs. Edelman, Pettus, and Wood also get into the clinical realities that shape real-world use: the 2:1 to 3:1 conversion versus subcutaneous insulin, the set-dose cartridges and how they reframe carb counting, a refined titration approach, side effects, and how inhaled insulin can be layered alongside pumps…
More episodes of Taking Control Of Your Diabetes® - The Podcast!
- Raising Kids with Type 1 Diabetes: Practical Advice Every Parent Needs with Raquel Baron
- Inhaled Insulin Just Got FDA-Approved for Kids With Type 1
Explore listener stats, chart rankings, contacts and more on the Taking Control Of Your Diabetes® - The Podcast! podcast page.